Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3035-3048

  Campos Martorell, Mireia ^a   Cano Sarabia, Mary ^a   Simats, Alba ^a   Hernández Guillamon, Mar ^a   Rosell, Anna ^a   Maspoch, Daniel ^a,b   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Brain; Delivery; Liposomes; Rat; Simvastatin; Stroke

Indexed keywords

LIPOSOME; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG UPTAKE; ENCAPSULATION; EX VIVO STUDY; EXPERIMENTAL CEREBRAL ISCHEMIA; LIPOSOMAL DELIVERY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT; ANIMAL; BIOAVAILABILITY; BRAIN; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; CHEMISTRY; DRUG EFFECTS; KIDNEY; LIVER; LUNG; METABOLISM; PROCEDURES; SPLEEN; STROKE; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; DRUG DELIVERY SYSTEMS; INFARCTION, MIDDLE CEREBRAL ARTERY; KIDNEY; LIPOSOMES; LIVER; LUNG; MALE; RATS, WISTAR; SIMVASTATIN; SPLEEN; STROKE; TISSUE DISTRIBUTION;

EID: 84979017193     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S107292     Document Type: Article

References (49)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
2. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340(23): 1781-1787.
3. García-Bonilla L, Campos M, Giralt D, et al. Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J Neurochem. 2012; 122(2):233-243.
4. Campos-Martorell M, Salvador N, Monge M, et al. Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model. J Neurochem. 2014;130(2):301-312.
5. Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke. 2001; 32(5):1112-1115.
6. Martí-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35(5):1117-1121.
7. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke. 2001;32(9):2185-2191.
8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977-987.
9. Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008; 14(1):37-44.
10. Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Investig. 2012;2(1):2-11.
11. Romana B, Batger M, Prestidge CA, Colombo G, Sonvico F. Expanding the therapeutic potential of statins by means of nanotechnology enabled drug delivery systems. Curr Top Med Chem. 2014;14(9):1182-1193.
12. Ishii T, Fukuta T, Agato Y, et al. Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced. Biochem Biophys Res Commun. 2013;430(4):1201-1205.
13. Sahagun G, Moore SA, Hart MN. Permeability of neutral vs. anionic dextrans in cultured brain microvascular endothelium. Am J Physiol. 1990; 259(1 pt 2):H162-H166.
14. García-Bonilla L, Sosti V, Campos M, et al. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res. 2011;1373:211-220.
15. Pérez-Asensio FJ, Hurtado O, Burguete MC, et al. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia. Neurobiol Dis. 2005; 18(2):375-384.
16. Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose-and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291(1): F116-F121.
17. Lowery A, Onishko H, Hallahan DE, Han Z. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release. 2011;72(2):181-204.
18. Afergan E, Ben David M, Epstein H, et al. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J. 2010;12(2):181-187.
19. Papagiannaros A, Kale A, Levchenko TS, Mongayt D, Hartner WC, Torchilin VP. Near infrared planar tumor imaging and quantification using nanosized Alexa 750-labeled phospholipid micelles. Int J Nanomedicine. 2009;4:123-131.
20. Zhang J, Rodila R, Gage E, et al. High-throughput salting-out assisted liquid/liquid extraction with acetonitrile for the simultaneous determination of simvastatin and simvastatin acid in human plasma with liquid chromatography. Anal Chim Acta. 2010;661(2):167-172.
21. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297-315.
22. Joo SP, Xie W, Xiong X, Xu B, Zhao H. Ischemic postconditioning protects against focal cerebral ischemia by inhibiting brain inflammation while attenuating peripheral lymphopenia in mice. Neuroscience. 2013;243:149-157.
23. Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods Mol Biol. 2010;605:1-27.
24. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv. 2011;2011:469679.
25. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428-437.
26. Kobeissy FH, Ottens AK, Zhang Z, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics. 2006;5(10):1887-1898.
27. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2): 283-318.
28. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
29. Gessner A, Lieske A, Paulke B, Müller R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm. 2002; 54(2):165-170
30. Hernández-Caselles T, Villalaín J, Gómez-Fernández JC. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol Cell Biochem. 1993;120(2):119-126.
31. Weiss L, Zeigel R, Jung OS, Bross ID. Binding of positively charged particles to glutaraldehyde-fixed human erythrocytes. Exp Cell Res. 1972;70(1):57-64.
32. Swaroop Kumar K, Jyothi T, Nagendar S, Devipriya S, Vijaya Kumar G, Sudhakar Babu AM. Stability of liposomes. Pak J Pharm Sci. 1995; 8(2):69-79.
33. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol. 1985;68(2):122-129.
34. Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 1996;739(1-2):88-96.
35. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54(13):3352-3356.
36. Schroeder A, Turjeman K, Schroeder JE, Leibergall M, Barenholz Y. Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants. Expert Opin Drug Deliv. 2010; 7(10):1175-1189.
37. Lu W. Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol. 2012;13(12):2340-2348.
38. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano-and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998; 46(3):255-263.
39. Cavaletti G, Cassetti A, Canta A, et al. Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. Mol Pharm. 2009;6(5):1363-1370.
40. Ernsting MJ, Murakami M, Roy A, Li S-D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172(3):782-794.
41. Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord. 2006;22(5-6):392-398.
42. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11(2):305-311.
43. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003;6(2):252-273.
44. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 suppl 1): III50-III57.
45. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos. 1990;18(2):138-145.
46. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993;24(3):195-202.
47. Lippert J, Brosch M, von Kampen O, et al. A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e13.
48. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004;34(11-12):961-971.
49. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci. 2008;33(4-5):317-325.